We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lipid Micelles May Replace Viruses for Gene Therapy

By Biotechdaily staff writers
Posted on 17 Apr 2006
Researchers have synthesized a lipid molecule with an exceptionally large, branched, and electrically charged head group that facilitates transfection of mammalian cells with genetic material and which may replace the use of viruses for this purpose.

Currently, engineered viruses are used as the vehicle for gene transplantation in more than 70% of clinical trials. More...
Another method, using DNA-lipid micelles, avoids problems of immune responses to the viral agent but is only being tested in about 10% of clinical trials. The main reason for this has been the lower efficiency of the micelles as compared to the viral vectors.

Investigators at the University of California, Santa Barbara (USA), have added a novel lipid molecule to the pool available for synthesis of DNA-lipid micelles. The molecule contains a highly charged (16+) multivalent cationic lipid, MVLBG2, with a large, highly branched nanoscale head group. The unusually large head group allows "honeycomb” interaction between the lipid and DNA molecules.

The investigators used their lipid-DNA micelles to transfect two lines of mouse and two lines of human tissue culture cells. One of the lines was comprised of mouse embryonic fibroblasts (MEF) that are notoriously difficult to transfect.

Results published in the March 29, 2006, issue of the Journal of the American Chemical Society revealed that the honeycomb structure of the lipid head group greatly enhanced the micelle's ability to transfer genetic material to the target cell. Senior author Dr. Cyrus R. Safinya, professor of molecular, cellular, and developmental biology at the University of California, Santa Barbara, said, Our data confirm that MEFs are generally hard to transfect. And the new molecule is far superior for transfection of these cells as compared to commercial lipids.”




Related Links:
University of California, Santa Barbara

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Rapid Sepsis Test
SeptiCyte RAPID
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.